Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Doroshow, James H."'
Autor:
Takebe N; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Naqash AR; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Kummar S; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Do K; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Bruns A; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Juwara L; Clinical Monitoring Research Program, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Zlott J; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Rubinstein L; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Piekarz R; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Sharon E; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Streicher H; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Mittra A; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Miller SB; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Ji J; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Wilsker D; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Chen L; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Chang TC; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Das B; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Mugundu G; AstraZeneca, Clinical Pharmacology, Waltham, Massachusetts., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. chenali@mail.nih.gov.; Center for Cancer Research, NCI, Bethesda, Maryland.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 15; Vol. 27 (14), pp. 3834-3844. Date of Electronic Publication: 2021 Apr 16.
Autor:
Konaté MM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA., Antony S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Publikováno v:
Antioxidants & redox signaling [Antioxid Redox Signal] 2020 Aug 20; Vol. 33 (6), pp. 435-454. Date of Electronic Publication: 2020 Apr 17.
Autor:
Lu J; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Risbood P; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA., Kane CT Jr; Starks Associates Inc., Buffalo, NY 14213, USA., Hossain MT; Starks Associates Inc., Buffalo, NY 14213, USA., Anderson L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA., Hill K; Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Monks A; Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wu Y; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Antony S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA., Juhasz A; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Liu H; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA., Jiang G; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Harris E; Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Roy K; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA., Meitzler JL; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Konaté M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA., Doroshow JH; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: doroshoj@mail.nih.gov.
Publikováno v:
Biochemical pharmacology [Biochem Pharmacol] 2017 Nov 01; Vol. 143, pp. 25-38. Date of Electronic Publication: 2017 Jul 11.
Autor:
Holleran JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Beumer JH; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27E, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA. beumerj@gmail.com., McCormick DL; IIT Research Institute, 10 West 35th Street, Chicago, IL, 60616, USA., Johnson WD; IIT Research Institute, 10 West 35th Street, Chicago, IL, 60616, USA., Newman EM; Department of Cancer Biology, City of Hope Beckman Research Institute, 1500 East Duarte Road, Duarte, CA, 91010, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 20892, USA., Kummar S; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 20892, USA., Covey JM; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 20892, USA., Davis M; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD, 20892, USA., Eiseman JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA. eisemanj@upmc.edu.; Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. eisemanj@upmc.edu.; University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27B, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA. eisemanj@upmc.edu.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2015 Oct; Vol. 76 (4), pp. 803-11. Date of Electronic Publication: 2015 Sep 01.
Autor:
Murai J; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research (Ju.M., J.H.D., Y.P.), National Clinical Target Validation Laboratory (Y.Z., J.J.), and Division of Cancer Treatment and Diagnosis (Jo.M., J.H.D.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan (Ju.M., S.T.)., Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2014 Jun; Vol. 349 (3), pp. 408-16. Date of Electronic Publication: 2014 Mar 20.
Autor:
Jaspers JE; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S
Publikováno v:
Cancer discovery [Cancer Discov] 2013 Jan; Vol. 3 (1), pp. 68-81. Date of Electronic Publication: 2012 Oct 25.
Autor:
Murai J; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA., Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y
Publikováno v:
Cancer research [Cancer Res] 2012 Nov 01; Vol. 72 (21), pp. 5588-99.
Autor:
Doroshow JH; Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA. doroshoj@mail.nih.gov, Juhasz A, Ge Y, Holbeck S, Lu J, Antony S, Wu Y, Jiang G, Roy K
Publikováno v:
Biochemical pharmacology [Biochem Pharmacol] 2012 May 01; Vol. 83 (9), pp. 1195-207. Date of Electronic Publication: 2012 Jan 24.
Autor:
Kummar S; Division of Cancer Treatment and Diagnosis, 31 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA., Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH
Publikováno v:
BMC medicine [BMC Med] 2012 Mar 09; Vol. 10, pp. 25. Date of Electronic Publication: 2012 Mar 09.
Autor:
Ji J; National Clinical Target Validation Laboratory, National Cancer Institute at Frederick, Frederick, Maryland, United States of America. jijiupi@mail.nih.gov, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH
Publikováno v:
PloS one [PLoS One] 2011; Vol. 6 (10), pp. e26152. Date of Electronic Publication: 2011 Oct 10.